Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

British Journal of Pharmacology

Volumn 171, Issue 6, 2014, Pages 1472-1489

  Rodríguez Cueto, Carmen ^a,b,c   Benito, Cristina ^a,d   Fernández Ruiz, Javier ^a,b,c   Romero, Julián ^d   Hernández Gálvez, Mariluz ^a,b,c   Gõmez Ruiz, María ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

cannabinoids; cerebellum; endocannabinoid system; Purkinje neurons; spinocerebellar ataxias

Indexed keywords

CALBINDIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; IBA 1 PROTEIN; NERVE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN REGION; CELL ACTIVATION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE NUCLEUS; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE INJURY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PURKINJE CELL; SPINOCEREBELLAR DEGENERATION; VERY ELDERLY; WHITE MATTER;

CANNABINOIDS; CB1 AND CB2 RECEPTORS; CEREBELLUM; ENDOCANNABINOID SYSTEM; PURKINJE NEURONS; SPINOCEREBELLAR ATAXIAS;

AGED; AGED, 80 AND OVER; CEREBELLUM; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPINOCEREBELLAR ATAXIAS;

EID: 84895752653     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12283     Document Type: Article

References (48)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
2. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I, (2007). Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412: 114-117. (Pubitemid 46074356)
3. Atwood BK, Mackie K, (2010). CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160: 467-479.
4. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, et al. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15: 300-302.
5. Benito C, Núñez E, Tolõn RM, Carrier EJ, Rábano A, Hillard CJ, et al. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23: 11136-11141. (Pubitemid 37548949)
6. Benito C, Kim WK, Chavarría I, Hillard CJ, Mackie K, Tolõn RM, et al. (2005). A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 25: 2530-2536. (Pubitemid 40365164)
7. Benito C, Romero JP, Tolõn RM, Clemente D, Docagne F, Hillard CJ, et al. (2007). Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27: 2396-2402. (Pubitemid 46340977)
8. Benito C, Tolõn RM, Pazos MR, Núñez E, Castillo AI, Romero J, (2008). Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 153: 277-285.
9. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M, (2007). The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28: 180-187. (Pubitemid 46483718)
10. De Yébenes J, (2010). Phase II-clinical trial on neuroprotection with cannabinoids in Huntington's disease (SAT-HD). EudraCT 2010-024227-24.
11. DeSanty KP, Dar MS, (2001). Cannabinoid-induced motor incoordination through the cerebellar CB1 receptor in mice. Pharmacol Biochem Behav 69: 251-259. (Pubitemid 32566270)
12. Durr A, (2010). Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 9: 885-894.
13. Fernández-Ruiz J, (2009). The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156: 1029-1040.
14. Fernández-Ruiz J, Romero J, Velasco G, Tolõn RM, Ramos JA, Guzmán M, (2007). Cannabinoid CB2 receptor: a new target for controlling neural cell survival. Trends Pharmacol Sci 28: 39-45. (Pubitemid 46038536)
15. Fernández-Ruiz J, García C, Sagredo O, Gõmez-Ruiz M, de Lago E, (2010). The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14: 387-404.
16. Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gõmez-Cañas M, Valdeolivas S, et al. (2011). Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163: 1365-1378.
17. Fratkin JD, Vig PJ, (2012). Neuropathology of degenerative ataxias. Handb Clin Neurol 103: 111-125.
18. 9-THCV in animal models of Parkinson's disease. Br J Pharmacol 163: 1495-1506.
19. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, et al. (2001). Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 78: 1415-1427. (Pubitemid 32899773)
20. Ishikawa K, Mizusawa H, Fujita T, Ohkoshi N, Doi M, Komatsuzaki Y, et al. (1995). Calbindin-D 28k immunoreactivity in the cerebellum of spinocerebellar degeneration. J Neurol Sci 129: 179-185.
21. Jin KL, Mao XO, Goldsmith PC, Greenberg DA, (2000). CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 48: 257-261. (Pubitemid 30617047)
22. Klockgether T, (2011). Update on degenerative ataxias. Curr Opin Neurol 24: 339-345.
23. Koeppen AH, Davis AN, Morral JA, (2011). The cerebellar component of Friedreich's ataxia. Acta Neuropathol 122: 323-330.
24. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN, (2005). Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437-445. (Pubitemid 41457512)
25. Matilla-Dueñas A, Corral-Juan M, Volpini V, Sanchez I, (2012). The spinocerebellar ataxias: clinical aspects and molecular genetics. Adv Exp Med Biol 724: 351-374.
26. Moldrich G, Wenger T, (2000). Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21: 1735-1742.
27. Núñez E, Benito C, Tolõn RM, Hillard CJ, Griffin WS, Romero J, (2008). Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are β-amyloid-linked events in Down's syndrome. Neuroscience 151: 104-110.
28. Orr HT, (2012). Cell biology of spinocerebellar ataxia. J Cell Biol 197: 167-177.
29. Pacher P, Mechoulam R, (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system. Prog Lipid Res 50: 193-211.
30. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, et al. (2009). Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132: 3152-3164.
31. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531. (Pubitemid 32938751)
32. Patel S, Hillard CJ, (2001). Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 297: 629-637. (Pubitemid 32377994)
33. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agrò A, et al. (2005). High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57: 777-779. (Pubitemid 40628874)
34. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, et al. (2009). WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 29: 2177-2186.
35. Robitaille Y, Schut L, Kish SJ, (1995). Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype. Acta Neuropathol 90: 572-581.
36. Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. (2009). Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 57: 1154-1167.
37. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J, (2011). Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res 89: 1509-1518.
38. Salazar M, Carracedo A, Salanueva IJ, Hernández-Tiedra S, Lorente M, Egia A, et al. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372.
39. Schnell SA, Staines WA, Wessendorf MW, (1999). Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 47: 719-730. (Pubitemid 29244510)
40. Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rüb U, (2012). Brain pathology of spinocerebellar ataxias. Acta Neuropathol 124: 1-21.
41. Shi SR, Cote RJ, Taylor CR, (2001). Antigen retrieval techniques: current perspectives. J Histochem Cytochem 49: 931-937. (Pubitemid 32675000)
42. Suárez J, Bermúdez-Silva FJ, Mackie K, Ledent C, Zimmer A, Cravatt BF, et al. (2008). Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 509: 400-421.
43. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM, (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411. (Pubitemid 28062631)
44. Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O, (2012). Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3: 400-406.
45. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, et al. (2006). Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 76: 89-101. (Pubitemid 44760539)
46. Witting A, Weydt P, Hong S, Kliot M, Moller T, Stella N, (2004). Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem 89: 1555-1557. (Pubitemid 38802677)
47. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6: 12.
48. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D, (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17: 2750-2754. (Pubitemid 36819300)